

10/634,713

16

PC25298A

REMARKS

Claims 1-14 are pending in the application.

Claims 1 and 8 are currently amended to delete non-elected subject matter.

Claims 10, 12, and 14 are canceled.

Claims 1-9, 11, and 13 would be all of the claims remaining in the application if the present amendments are entered.

Elections/Restrictions

In the Office Action, restriction under 35 U.S.C. § 121 was required. Applicants hereby elect without traverse the invention of Group I, which was described in the Office Action as follows:

Claims 1-9, 11-14, drawn to a compound of formula I wherein D is pyrazinone or formula II or IV, composition and method of use, classified in class 544, subclasses 384, 385, and others, class 514, subclass 255.02 and others depending upon the choice of preferred embodiments of the other variable groups of formula I.

Claims 1-9, 11, and 13 read on the invention of Group I.

Applicants also elect under 35 U.S.C. § 121 the single disclosed species, 4-[5-(3-benzylcarbamoyl-2,6-dioxo-3,6-dihydro-2H-pyrazin-1-yl)-tetrazol-2-yl]-benzoic acid, which is the first species of claim 9. Claims 1-4, 6, 8, 9, 11, and 13 read on the elected species.

Conclusion

In view of the above amendment and remarks, Applicants believe that the restriction requirements are met and request consideration of claims 1-9, 11, and 13.

Respectfully submitted,

Date: October 7, 2005

Claude F. Purchase, Jr.

Claude F. Purchase, Jr.
Reg. No. 47,871
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1692
Fax (734) 622-1553